Idogen presents at Stora Aktiedagen in Gothenburg November 4th

Monday November 4th at 09.20 Idogen’s CEO Anders Karlsson will present the company at Stora Aktiedagen in Gothenburg at Svenska Mässan, Mässans Gata 24 (entrence via Hotel Gothia Towers). New and future shareholders are warmly welcome. 

For program and registration, please visit https://www.aktiespararna.se/aktiviteter/stora-aktiedagen-goteborg-2019

The presentation will be in english, and be availible live and on demand via: www.aktiespararna.se/tv/evenemang

For additional information, please contact:
Anders Karlsson, VD Idogen AB 
Phone: +46 (0) 709 18 00 10 
Email: anders.karlsson@idogen.com 

Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit www.idogen.com

Tags: